BRONHALAMIN BRONCHUSES BIOREGULATOR. CONTRIBUTES TO THE NORMALIZATION AND IMPROVEMENT OF FUNCTIONS OF THE BRONCHOPULMONARY SYSTEM WITH VARIOUS VIOLATIONS, PREVENTS THE DEVELOPMENT OF DYSPNEA AND BRONCHOSPASM.
Currently out of stock.
Bronhalamin®- bronchuses bioregulator.
Contributes to the normalization and improvement of functions of the bronchopulmonary system with various violations, prevents the development of dyspnea and bronchospasm.
At diseases of of the lungs and bronchial tubes of different etiology in patients developing ventilation and metabolic disorders that lead to arterial hypoxemia, pulmonary lesion of the endothelium and epithelium of the bronchi, which ultimately causes a decrease in lung ventilation and the development of respiratory failure. For the normalization and correction of pathological changes in the lung and bronchial system resulting from diseases of different etiologies have been developed one type of Cytamins - "Bronhalamin".
Clinical trials of "Bronhalamin" conducted on 98 patients with chronic asthmatic bronchitis, the main complaints of patients manifested as cough with phlegm, mostly in the morning, general weakness, shortness of breath on exertion, recurrent attacks of breathlessness, sleep disorders, headaches. "Bronhalamin" used in the complex therapy. During clinical trials, all patients underwent a comprehensive examination including clinical, laboratory and instrumental studies.
According to the results of clinical trials found that when using the "Bronhalamin" in 68% of patients with chronic bronchitis improved overall health and reduce the frequency of attacks of coughing and choking, decreased the number of sputum. The positive dynamics in the lung auscultation picture in the form of reducing the number of wheezing, as well as the normalization of the microscopic picture of the bronchial secretions, which reflects the general trend of reduction of inflammatory and bronchospastic disease manifestations. Lung function tests showed a compensation of the pathological process in the lungs. The use of "Bronhalamin" had a positive impact on the dynamics of this process.
It is found that, despite the positive changes in the state of patients receiving "Bronhalamin" in cases where the disease continues for more than 5 years, it is optimal for the re-admission "Bronhalamin" 1.5 months after the initial reception.
Results from clinical studies suggest therapeutic efficacy of "Bronhalamin" and appropriateness of its use in treatment, as well as for the prevention of various diseases of broncho-pulmonary system.
Positive results were also obtained when using the "Bronhalamin" athletes of the highest category. It is found that the use of "Bronhalamin" in the process of preparing athletes to compete allowed to increase aerobic capacity and performance of the oxygen pulse, breathing reserve increase, leading not only to the increase in physical performance by 15-20% compared to baseline, but also keep it to the end sports season.
Optimum is a comprehensive application of the "Bronhalamin" with "Timusamin" and "Suprenamin" - when asthmatic conditions and "Koramin" - in pulmonary and cardiovascular disease, respiratory diseases as often arise or occur against the background of immunodeficiency. Repeated course - 3-6 months.
Indication of use:
1-3 tablets 2-3 times a day for 10-15 minutes before meals with water without chewing. Course: 10-14 days. Repeat the course in 3-6 months.
Individual intolerance to the product components, pregnancy, lactation.
40 tablets per pack